**4.2 Zafirlukast**

94 Otolaryngology

Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal AR have not been established. The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended: 10 mg for adults and adolescents 15 years of age and older; 5 mg for pediatric patients 6 to 14 years of age; 5 mg for pediatric patients 2 to 5 years of age; 4 mg for pediatric patients 6 to 23 months of age. Safety and effectiveness in pediatric

Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT1 receptor (in preference to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or β-adrenergic receptor). Montelukast inhibits physiologic

The efficacy of montelukast for the treatment of persistent and seasonal AR was investigated






patients younger than 6 months of age with perennial AR have not been established.

actions of LTD4 at the CysLT1 receptor without any agonist activity.

of treatment in patients with persistent AR (Ciebiada et al, 2011).

in different studies and clinical trials.

*Evidence in persistent AR:* 

(Patel et al, 2005).

*Evidence in persistent AR:* 

daily therapy (Weinstein et al, 2005).

Donnelly et al performed a study with 164 patients who were administered increasing doses of oral Zafirlukast (10, 20, 40, 100 mg and placebo). They found a significant decrease in nasal obstruction, sneezing and rhinorrhoea in patients who received doses starting from 20 mg (Donnelly et al, 1995)
